Antidepressant Relabeling Will Include Pediatric Efficacy Data
FDA's plan for relabeling antidepressants to address pediatric safety concerns will involve some negotiation with sponsors over how best to present efficacy data
FDA's plan for relabeling antidepressants to address pediatric safety concerns will involve some negotiation with sponsors over how best to present efficacy data